All articles by Phillip Broadwith – Page 11
-
Opinion
Toeing the advertising line
Companies have to tread a little carefully when it comes to advertising prescription drugs
-
BusinessBuilding better bottles
Catalytic Technologies wants to replace antimony catalysts in polyester production with safer, more active titanium
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment
-
Business
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
-
Business
Job cuts at Daiichi, Perrigo and Cabot
Staff reductions aimed at cutting costs or, in Perrigo’s case, fending off a takeover bid
-
Business
Nine dead in China plant blast
Explosion in Shandong province latest of several incidents in Chinese chemical plants
-
Business
Safety board fills in details of deadly DuPont leak
In interim investigation has outlined the events and safety failings leading to a methyl mercaptan release that killed four workers
-
Opinion
Human capital
Business leader: Incubators and hubs for small and medium-sized enterprises are all the fashion
-
Opinion
Drugs in a class of their own
New drug types need careful regulation to reward innovation while protecting patients
-
Business
Syngenta fends off Monsanto takeover bid
Unmoving objection to merger leads US giant to drop pursuit
-
Business
Berry plastics to buy Avintiv for $2.5bn
Deal helps Berry diversify from food packaging into speciality medical materials
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
Business
Lightweight composites drive Solvay to buy Cytec
$5.5bn deal launches Solvay into aerospace materials business
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
Business
Biogen to develop gene therapies with AGTC
$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases
-
Business
Three dead in Chinese petrochemical plant fire
Further four workers injured after leaking oil ignited at Qingyang Petrochemical plant in Gansu province